Add Company
Join Now

Gracell Biotechnologies Revenue and Competitors

License our Company Data API

上海市,

Location

N/A

Total Funding

Tech Services

Industry

Estimated Revenue & Valuation

  • Gracell Biotechnologies's estimated annual revenue is currently $1.2M per year.(i)
  • Gracell Biotechnologies's estimated revenue per employee is $101,500
  • Gracell Biotechnologies's current valuation is $309.8M. (January 2022)

Employee Data

  • Gracell Biotechnologies has 12 Employees.(i)
  • Gracell Biotechnologies grew their employee count by -40% last year.

Gracell Biotechnologies's People

NameTitleEmail/Phone
1
Senior Director Investor Relations & Corporate CommunicationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$60M33124%N/AN/A
#2
$5.3M46-6%N/AN/A
#3
$36.8M236-3%$46.9MN/A
#4
$15.1M1044%N/AN/A
#5
$1.4M16-6%N/AN/A
#6
$1.4M16-6%N/AN/A
#7
$3.5M30-12%N/AN/A
#8
$146M7196%N/AN/A
#9
$99.7M550-1%N/AN/A
#10
$12.9M89-3%$3.5MN/A
Add Company

What Is Gracell Biotechnologies?

亘喜生物科技(上海)有限公司 is an information technology and services company based out of 上海市徐汇区宜山路926号1幢12层, 上海市, 上海市, China.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$1.2M

Revenue (est)

-40%

Employee Growth %

$309.8M

Valuation

N/A

Accelerator

Gracell Biotechnologies News

2022-04-13 - Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 ...

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual...

2022-04-06 - Gracell Biotechnologies to Present Data at AACR Annual ...

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL.

2022-03-30 - Gracell Biotechnologies to Participate in Three Investor ...

PALO ALTO, Calif. and SUZHOU, China, March 29, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”),...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A120%N/A
#2
$1.5M120%N/A
#3
$1.1M120%N/A
#4
$1.8M129%N/A
#5
N/A130%N/A